ONCOLife Warmly Welcomes Dr İlkiz Er Dağ as ONCOLife Project Director

ONCOLife is delighted to announce that Dr İlkiz Er Dağ, MD, MBA, has joined the company as Project Director for Oncology Training Programs, a newly created post that reflects the organisation’s commitment to reshaping how oncologists learn in the age of artificial intelligence. In this strategic role Dr. Er Dağ will oversee the full spectrum of ONCOLife’s educational portfolio—including live symposia, virtual summits, e-learning modules and AI-assisted micro-learning pathways—for practising oncologists across the United States and the European Union.

Dr. Er Dağ held  her medical degree and pathology specialty at Ege University Medical Faculty, completed an MBA  program sponsored by Novartis at Boğaziçi University. She brings more than 15 years of experience in medical affairs , clinical research and healthcare communications, having held leadership posts at GlaxoSmithKline, Novartis Oncology, AbbVie and, most recently, Memorial Health Group before founding her own consultancy in 2024.

Throughout her career she has designed and executed high-impact education and access initiatives. Among her signature achievements are one of largest Myelofibrosis Early-Access Programme and the country’s first interventional Phase II oncology study of nilotinib—work that produced peer-reviewed publications and international congress presentations. Her efforts regarding access strategies have been recognised with two AbbVie President’s Awards and a Novartis Global Best-Practice citation.

Reporting directly to the executive leadership team, Dr. Er Dağ will spearhead the rollout of ONCOLife’s next-generation training suite. This includes modular online masterclasses that adapt to individual learning curves, interactive tumour-board workshops streamed from leading centres, and an AI assistant that curates literature and guideline updates in real time. She will also coordinate market-specific faculty networks to ensure each programme meets local regulatory and clinical practice needs in both the US and EU.

“I am honoured to join ONCOLife at such a pivotal moment,” Dr. Er Dağ said. “By fusing evidence-based content with adaptive technology we can shorten the distance between discovery/innovation  and bedside care—ultimately improving outcomes for patients worldwide. I look forward to collaborating with our faculty, partners and the wider oncology community to make that vision a reality.”